Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations

BACKGROUND: Epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer predict dramatic clinical responses to tyrosine kinase inhibitor (TKI) treatment. The conclusion on EGFR mutation-specific antibodies by immunohistochemistry (IHC) is not consistent. We evaluated the clinical...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Zhang, Ruiguang, Li, Yan, Nie, Xiu, Dong, Xiaorong, Wu, Gang
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2016
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4723025/
https://ncbi.nlm.nih.gov/pubmed/26848271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S95785
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky